（编辑 丛可心） 证券日报网讯 2月26日，回盛生物在互动平台回答投资者提问时表示，公司密切关注AI技术在兽药行业 的发展与应用，将AI等先进数字技术融入公司研发、生产、经营管理等方面。目前，公司在研发项目 过程中，也在运用AI技术以提高研发效率，但相关研究短期内不会对公司经营业绩产生直接影响。 ...

证券日报网讯2月24日，普莱柯（603566）在互动平台回答投资者提问时表示，公司多款禽腺病毒系列 联苗已获得新兽药注册证书并推向市场；禽流感(H5+H7)重组杆状病毒载体三价灭活疫苗、猪伪狂犬病 活疫苗(五基因缺失株)等近10项产品已通过新兽药注册初审或进入复核检验阶段；禽传染性支气管炎(悬 浮培养技术)系列联苗、犬四联活疫苗、犬三联活疫苗等产品已提交新兽药注册申报；猪流行性腹泻基 因工程亚单位疫苗、禽流感(悬浮培养技术)系列联苗等产品处于临床试验阶段；此外，数十项畜禽用和 宠物用疫苗、化学药品尚处于实验室研究阶段。 ...

来源：智通财经 文 | 周涛 山东宠物经济或再壮大。 2026年2月16日，一家来自山东潍坊诸城的"隐形冠军"企业——山东信得科技股份有限公司，向香港联 合交易所递交了主板上市申请，为自己的资本市场之旅按下了启动键。 图片来源：港交所 根据灼识咨询的报告，以2024年收入计，信得科技在中国动物保健市场的国产厂商中排名第九，市场份 额约为1.4%。 然而，其真正的核心竞争力体现在更为细分的领域：在中国禽用兽用生物制品市场，公司稳居前三。 | 量纂]的[编纂]數目 : [編纂]股H股(視乎[編纂] | | | | --- | --- | --- | | 行使與否而定) | | | | [編纂]數目 | .. | [編纂]股H股(可予[編纂]) | | [編纂]數目 | . . | [編纂]股H股(可予[編纂]及視乎[編纂] | | 行使與否而定) | | | | 最高[編纂] | .. | 每股H股[編纂]港元,另加1.0%經紀 | | 佣金、0.0027%證監會交易徵費、 | | | | 0.00015%會財局交易徵費及0.00565% | | | | 香港聯交所交易費(須於[編纂]時以港 | | | | 元繳 ...

公司新兽药注册证书于2026年2月9日获批，产品为猪圆环病毒2型重组杆状病毒灭活疫苗(CH17株，悬 浮培养)，用于预防猪圆环病毒2型感染引起的疾病。 以上内容基于公开资料整理，不构成投资建议。 经济观察网科前生物(688526)近期获得农业农村部批准的新兽药注册证书，产品为猪圆环病毒2型重组 杆状病毒灭活疫苗(CH17株，悬浮培养)，用于预防猪圆环病毒2型感染引起的疾病。该产品的获批将丰 富公司产品线，但上市销售前还需取得产品批准文号，市场推广和销售情况存在不确定性。 产品研发进展 ...

科前生物公告称，经 农业农村部审查，公司申报的猪圆环病毒2型重组杆状病毒灭活疫苗获批新兽药， 获《新兽药注册证书》，注册分类为三类，监测期3年。该疫苗用于预防猪圆环病毒2型感染疾病，免疫 后28日产生免疫，主动免疫持续4个月，仔猪被动免疫至21日龄。产品获批将丰富公司产品种类，提升 竞争力，但上市前需取得批准文号，生产销售时间及效益存在不确定性。 ...

Group 1 - The company announced the approval of a synthetic biology manufacturing project in Xinjiang, with a total investment of 1 billion yuan, to be constructed in three phases [2][5] - The project aims to meet market demand, overcome capacity and efficiency bottlenecks, and achieve technological upgrades and cost control [2][6] - The project aligns with the encouraging industrial policies of the western region, allowing the company to benefit from local tax incentives and meet green development requirements [2][6] Group 2 - The company specializes in the animal health sector, focusing on the research, production, and sales of veterinary drugs, feed, and additives [4][8] - The company has achieved full coverage in the top 10 of the national pig farming industry and has established stable partnerships with many large domestic farming enterprises [5][8] - The projected sales revenue for 2024 is 1.2 billion yuan, representing a year-on-year growth of 17.71% [5][8] - The company currently has a production capacity of 2,000 tons for Tylosin and 840 tons for Tiamulin [5][8]

Core Viewpoint - Jinhe Biological Technology Co., Ltd. forecasts a net profit attributable to shareholders of 30 million to 42 million yuan for 2025, despite planning to recognize goodwill impairment of approximately 150 million yuan, which will reduce the net profit to an estimated 180 million to 192 million yuan without the impairment [1][2]. Group 1: Financial Performance - The sales of the veterinary chemical drug segment are expected to continue improving, with significant growth in both domestic and overseas markets, particularly for the main product, chlortetracycline [1]. - The environmental services segment is also contributing positively to the company's revenue, indicating a diversified income stream [1]. - The company is taking a cautious approach to goodwill impairment, which is seen as a strategic decision rather than a sign of operational pressure [1]. Group 2: Core Business Strengths - The veterinary chemical drug segment has become the core area for the company, with chlortetracycline achieving both volume and price increases due to expanded application scenarios and recovering downstream demand [2]. - The company has 16 vaccine products on the market, with a leading market share in domestic blue ear disease vaccines and a high penetration rate among top pig farming enterprises [2]. - The company has a robust pipeline with over 20 products in development, including a recently approved inactivated vaccine for porcine encephalitis, enhancing its product matrix [2]. Group 3: New Business Initiatives - Jinhe Biological is actively developing two emerging business areas: pet products and synthetic biology, aiming to cultivate new growth curves [3]. - The pet segment has a diverse product matrix, including 15 chemical and vaccine products, with several more in the application process [3]. - The synthetic biology initiative has achieved a significant milestone with the approval of a feed additive, marking the commercialization of a 3,000-ton astaxanthin project, which has broad applications across various industries [3]. Group 4: Future Development Strategy - The company plans to prioritize the pet business as a strategic focus to create new performance growth points [3]. - The veterinary chemical drug segment will continue to center around chlortetracycline while developing a multi-category chemical drug collaborative model [3]. - The veterinary biological products segment aims to leverage research and technology to become a leading player in the domestic veterinary vaccine industry, establishing a second growth curve for the company [3].

本报告期，公司兽用化学药品板块销售持续向好，主要产品金霉素内外销市场销量齐增，特别是海外市 场销量继续增长。公司六期工程项目投产后，产量增加，保障了国内外市场供货需求，创造了更多利 润。环保服务板块营业收入继续增加，持续提供较多的业绩贡献。 格隆汇1月30日丨金河生物(002688.SZ)公布，预计2025年归属于上市公司股东的净利润3,000万元～ 4,200万元，比上年同期下降70.06%～58.08%，扣除非经常性损益后的净利润950万元～1,350万元，比 上年同期下降88.66%～83.89%。 ...

Core Viewpoint - The company held its first extraordinary board meeting of 2026, where several key resolutions were passed, including the approval of bank credit limits and related party transactions for the year [1][2][4][6][10]. Group 1: Bank Credit and Financing - The board approved a total bank credit limit of 5.771 billion yuan for 2026, with 1.960 billion yuan allocated to the headquarters and 3.811 billion yuan to subsidiaries [2]. - Additionally, the company and its subsidiaries will apply for project financing credit totaling 1.145 billion yuan, with 740 million yuan for the headquarters and 405 million yuan for subsidiaries [2]. Group 2: Related Party Transactions - The board approved ongoing sales of poultry vaccines and veterinary medicines to Shandong Zhongxin Food Group Co., Ltd., with an estimated transaction amount not exceeding 24 million yuan for 2026 [4][14]. - The company will also continue to purchase production raw materials from Xiamen Jindawei Group Co., Ltd., with an estimated transaction amount not exceeding 31 million yuan for 2026 [6][16]. Group 3: Internal Audit and Salary Budget - The board approved the internal audit plan for 2026 [8][9]. - The board also approved the salary budget for 2025, along with the evaluation report for the total salary for 2024 [10][11]. Group 4: Upcoming Shareholder Meeting - The board agreed to convene the second extraordinary shareholder meeting of 2026 to discuss additional matters requiring shareholder approval [11]. Group 5: Performance Forecast - The company anticipates a net profit attributable to shareholders of 148.59 million to 192.29 million yuan for 2025, representing an increase of 77.70 million to 121.41 million yuan compared to the previous year, which is a year-on-year increase of 109.62% to 171.27% [32][33]. - However, the net profit after deducting non-recurring gains and losses is expected to be between 16.90 million and 23.24 million yuan, a decrease of 38.90 million to 45.24 million yuan compared to the previous year, reflecting a year-on-year decrease of 62.60% to 72.80% [33]. Group 6: Reasons for Performance Increase - The increase in net profit is attributed to gains from investments, including the subscription of convertible bonds issued by Xiamen Jindawei Group and the abandonment of the right of first refusal for shares in Zhongpu Biopharmaceutical Co., Ltd. [37]. - The company has also optimized its marketing structure and product development to enhance operational efficiency [37].

Core Viewpoint - The company, *ST Green Health, is expected to report a negative net profit for the fiscal year 2025, marking the first accounting year after the implementation of financial delisting risk warning on its stock [1][10]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025, with an anticipated net profit being negative [1]. - The company has completed a significant asset restructuring, transferring 100% equity of three subsidiaries to another company, which will affect the financial results [2]. Group 2: Communication with Auditors - The company has communicated with its auditing firm regarding the performance forecast, and there are no significant disagreements as of the announcement date [3]. Group 3: Reasons for Performance Changes - The main reason for the performance change is the separation of the loss-making photovoltaic film business, which will no longer be included in the consolidated financial statements [4]. - Despite the expected loss, the veterinary medicine business has seen revenue growth, primarily from higher-margin products, leading to an overall improvement in gross margin compared to 2024 [4]. Group 4: Risk of Delisting - The company reported a negative net asset value of -24,536,065.37 yuan as of the end of 2024, triggering a delisting risk warning [10][14]. - The net profits attributable to shareholders for 2022, 2023, and 2024 were -121,938,109.79 yuan, -221,817,878.58 yuan, and -444,864,018.29 yuan respectively, indicating a continuous decline [11][14]. - If the company’s financial indicators trigger delisting rules again in 2025, the stock may face termination of listing [24]. Group 5: Audit Progress - The auditing firm, Lixin, has been conducting the 2025 annual audit since November 2025, and there are no major disagreements on significant accounting treatments or key audit matters [25][26]. - The company is actively progressing with the preparation and auditing of the 2025 annual report [25].